RecruitingPhase 4Drug trialA Study Evaluating the Efficacy of Secukinumab 300mg in Chinese Adults With Active Ankylosing SpondylitisThe purpose of this study is to evaluate the safety and efficacy of secukinumab 300mg in Chinese adults participants with active ankylosing spondylitis (AS) who have had an inadequate response to at least 2 non-steroidal anti-inflammatory drugs (NSAIDs) or intolerance to or a contraindication for NSAIDs, and who are naïve to biologic disease-modifying anti-rheumatic drugs (bDMARD).